Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC

Part of paid clinical trials in Atlanta, Georgia.

Sponsor
Geneos Therapeutics
Study ID
NCT07722741
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • GNOS-PV02 + INO-9012 delivered by intradermal injection, followed by electroporation — BIOLOGICAL
    delivered by intradermal injection and electroporation
  • Electroporation Device — DEVICE
    GNOS-PV02 + INO-9012 ID followed by electroporation
  • INO-9012 — BIOLOGICAL
    cytokine interleukin-12 (IL-12), a vaccine adjuvant

Study Details

This is a randomized, open-label, multi-site Phase II study of a personalized neoantigen DNA vaccine (GNOS-PV02) and plasmid encoded IL-12 (INO-9012) in subjects with histologically or cytologically confirmed diagnosis of HCC based on pathology report, who were eligible to undergo definitive resection, have demonstrated laboratory, radiographic and/or pathologic high-risk criteria for recurrence (described under eligibility), have no evidence of disease (NED) as per MRI approximately 28 days post resection, and are able to provide a tissue sample for personalized neoantigen DNA vaccine development.

Key Dates

First listed
Jul 23, 2026
Start date
Sep 30, 2026
Status verified
Aug 2026
Primary completion
Sep 30, 2029
Completion
Jun 30, 2032

Study Design

Enrollment
90 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Personalized Immunotherapy for Cancer:
    GNOS-PV02 + INO-9012 ID followed by electroporation every 3 weeks for 4 doses, then every 9 weeks (Q9W) until week 104, then every 12 weeks (Q12W) until week 260 followed by 3 years follow-up survival
  • No Intervention: Standard of Care
    Active Surveillance for 5 years or until recurrence, plus 3 years follow-up survival.

Primary Outcome Measure

Recurrence-free survival [ Time Frame: Up to 5 years ]

Central Contacts

Locations (7)

FacilityCityStateZIPSite coordinators
Emory UniversityAtlantaGeorgia30322
Principal Investigator, MD
[email protected]
404-251-1278
Louisiana State University Health Sciences CenterNew OrleansLouisiana70112
Principal Investigator, MD
[email protected]
504-568-4750
Johns Hopkins UniversityBaltimoreMaryland21287
Principal Investigator, MD
[email protected]
410-955-8893
University of MichiganAnn ArborMichigan48109
Principal Investigator, MD
[email protected]
734-936-8643
Icahn School of Medicine at Mount SinaiNew YorkNew York10029
Principal Investigator, MD
[email protected]
212-241-7840
MD Anderson Cancer CenterHoustonTexas77030
Principal Investigator, MD
[email protected]
713-792-2828
Fred Hutchinson Cancer CenterSeattleWashington98109
Principal Investigator, MD
[email protected]
206-667-1392

Find similar trials in Atlanta, GA

Nationwide
Liver cancer trialsOncology trialsGI oncology trialsHepatology trials
By condition
Liver cancer
By specialty
OncologyGI oncologyHepatology
By research site
Emory University· Atlanta, GALouisiana State University Health Sciences Center· New Orleans, LAJohns Hopkins University· Baltimore, MDUniversity of Michigan· Ann Arbor, MIIcahn School of Medicine at Mount Sinai· New York, NYMD Anderson Cancer Center· Houston, TX

Related Studies